Business
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company
About this update from Collegium Pharmaceutical, Inc.
[{"type":"text","content":"STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that 10 poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2023, being held in Las Vegas, NV from September 5–8, 2023. “Collegium is dedicated to responsible pain management and leading with science. We are pleased to present 10 posters with new real-world data at PAINWeek 2023 that underscore the clinical and population health impact of our portfolio and provide significant insights for healthcare decision makers who treat people experiencing pain,” said Thomas Smith, M.D., Chief Medical Officer of Collegium. “We welcome opportunities to share clinical and real-world data with the medical community as part of our commitment to improving the lives of people living with serious medical conditions.” The following poster presentations will also be available on the PAINWeek Conference 2023 website on Wednesday, September 6, 2023, from 3:30 – 4:30 p.m. PT and on Thursday, September 7, 2023, from 3:30 – 5:30 p.m. PT. Poster Presentations: Poster Title:Healthcare Cost and Resource Use in Chronic Low Back Pain Patients Treated with Belbuca® and Buprenorphine Transdermal Patches: A Retrospective US Commercial Claims AnalysisAuthors:Vladimir Zah, Filip Stanicic, Todd Kunkel, Djurdja Vukicevic, Dimitrije Grbic Poster Title:Treatment Characteristics of Chronic Low Back Pain Patients Treated with Belbuca® and Buprenorphine Transdermal Patches: A Retrospective US Commercial Claims AnalysisAuthors:Vladimir Zah, Filip Stanicic, Todd Kunkel, Djurdja Vukicevic, Dimitrije Grbic Poster Title:Safety and Tolerability of Buprenorphine and Oral Schedule II Opioid Treatment in Chronic Low Back Pain Patients: A Retrospective US Commercial Claims AnalysisAuthors:Vladimir Zah, Filip Stanicic, Todd Kunkel, Djurdja Vukicevic, Dimitrije Grbic Poster Title:Healthcare Costs Associated with Rates of Prescription Opioid Misuse/AbuseAuthors:Jody L. Green, Taryn Dailey-Govoni, Suzanne K. Vosburg Poster Title:Sustained Risk Reduction of Severe Clinical Outcomes Following Misuse/Abuse of XTAMPZA® ER as Compared to Other Prescription OpioidsAuthors:J...